Table 2.
High-density lipoprotein (HDL) function markers after 4 weeks of agraz consumption, compared to placebo, in women with metabolic syndrome.
| Variables | Placebo | Agraz | Δ Change (Agraz-Placebo) Mean ± SD | p | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Mean ± SD | n | Mean ± SD | |||||||||
| HDL function markers | ||||||||||||
| Apo A1 (mg/dL) | 34 | 127.6 | ± | 43.1 | 29 | 132 | ± | 49 | 3.1 | ± | 40.8 | 0.597 |
| PON1 Arylesterase Activity (kU/L) | 38 | 77.1 | ± | 17.5 | 38 | 76.5 | ± | 17.5 | −0.7 | ± | 8.8 | 0.643 |
| PON1 Lactonase Activity (kU/L) | 38 | 12.6 | ± | 2.7 | 38 | 12.6 | ± | 2.8 | 0.2 | ± | 1.6 | 0.862 |
| Cholesterol efflux (%) | 27 | 8.2 | ± | 3.6 | 27 | 8.7 | ± | 3.8 | 0.5 | ± | 2.9 | 0.324 |
| HDL-related oxidative markers | ||||||||||||
| MPO (ng/mL) | 34 | 177.8 | ± | 74.6 | 34 | 175 | ± | 72.7 | −11.1 | ± | 72 | 0.795 |
| MPO/PON1 arylesterase ratio | 34 | 2.7 | ± | 1.6 | 34 | 2.6 | ± | 1.3 | −0.1 | ± | 1.2 | 0.770 |
| MPO/PON1 lactonase ratio | 34 | 15.5 | ± | 7.4 | 34 | 14.9 | ± | 6.9 | −0.7 | ± | 6.7 | 0.515 |
| AOPP (µM) | 29 | 99.5 | ± | 20.9 | 29 | 97.5 | ± | 17 | −2.0 | ± | 19.8 | 0.703 |
SD, standard deviation; Apo, apolipoprotein; PON1, paraoxonase 1; MPO, myeloperoxidase; AOPP, advanced oxidation protein products. Paired t-test was used for the analysis. Significance p < 0.05.